Philadelphia Chromosome Positive clinical trials at UC Davis
1 research study open to eligible people
“Do you have b-cell acute lymphoblastic leukemia and have relapsed or are no longer responding or benefiting from the treatment?”
open to eligible people ages 18 years and up
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.